Platinum containing medications

9,118views

Platinum containing medications

Watch later

Watch later

Introduction to pharmacology
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Agonist, partial agonist and antagonist
Pharmacodynamics: Desensitization and tolerance
Pharmacokinetics: Drug absorption and distribution
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Drug administration and dosing regimens
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
ACE inhibitors, ARBs and direct renin inhibitors
Miscellaneous lipid-lowering medications
Lipid-lowering medications: Fibrates
Lipid-lowering medications: Statins
cGMP mediated smooth muscle vasodilators
Calcium channel blockers
Positive inotropic medications
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
Adrenergic antagonists: Presynaptic
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Hyperthyroidism medications
Hypothyroidism medications
Mineralocorticoids and mineralocorticoid antagonists
Adrenal hormone synthesis inhibitors
Acid reducing medications
Antidiarrheals
Laxatives and cathartics
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Hematopoietic medications
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Anti-tumor antibiotics
Microtubule inhibitors
Platinum containing medications
Topoisomerase inhibitors
Ribonucleotide reductase inhibitors
Glucocorticoids
Non-corticosteroid immunosuppressants and immunotherapies
Cell wall synthesis inhibitors: Penicillins
Cell wall synthesis inhibitors: Cephalosporins
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Aminoglycosides
Protein synthesis inhibitors: Tetracyclines
Miscellaneous protein synthesis inhibitors
DNA synthesis inhibitors: Fluoroquinolones
DNA synthesis inhibitors: Metronidazole
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Integrase and entry inhibitors
Protease inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Hepatitis medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anti-mite and louse medications
Anthelmintic medications
Antimalarials
Acetaminophen (Paracetamol)
Antigout medications
Non-steroidal anti-inflammatory drugs
Osteoporosis medications
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
General anesthetics
Local anesthetics
Migraine medications
Nonbenzodiazepine anticonvulsants
Neuromuscular blockers
Anti-parkinson medications
Medications for neurodegenerative diseases
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid antagonists
Sympathomimetics: Direct agonists
Tricyclic antidepressants
Atypical antidepressants
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Monoamine oxidase inhibitors
Psychomotor stimulants
Typical antipsychotics
Atypical antipsychotics
Lithium
Loop diuretics
Carbonic anhydrase inhibitors
Osmotic diuretics
Potassium sparing diuretics
Thiazide and thiazide-like diuretics
Androgens and antiandrogens
Estrogens and antiestrogens
Progestins and antiprogestins
Uterine stimulants and relaxants
Aromatase inhibitors
PDE5 inhibitors
Antihistamines for allergies
Pulmonary corticosteroids and mast cell inhibitors
Bronchodilators: Leukotriene antagonists and methylxanthines
Bronchodilators: Beta 2-agonists and muscarinic antagonists

Transcript

Watch video only

Platinum containing agents, informally called platins, are a class of medications that are used to treat cancer.

They disrupt the structure of DNA by acting on consecutive guanine bases within a strand of DNA and can affect all phases of the cell cycle.

Okay, now the cell cycle refers to the events that somatic cells, which includes all of the cells in our bodies except the reproductive cells, go through from the moment they’re formed until the moment they divide into two identical daughter cells.

This cycle varies in length depending on the type of cell.

For rapidly dividing cells, like skin cells, it takes less than a day, whereas for other cells, like liver cells, the cell cycle can last years.

Now, the cell cycle can be divided in two phases: interphase and mitosis.

Interphase comprises of the G1 phase, during which the cell grows and performs its cell functions, the S phase, during which DNA is replicated, and the G2 phase, during which the cell grows again before entering mitosis.

Mitosis can be broken down into prophase, metaphase, anaphase, and telophase, during which the replicated DNA divides equally for the two daughter cells, and ends with cytokinesis, which is when the cell membrane actually divides to form the two new cells.

There’s also a G0 phase which is an extended G1 phase, where the cell is resting and not actively preparing to divide.

Alright, now imagine a cancer cell.

This cell is going through the phases of the cell cycle without regulation, and its DNA also replicates more frequently, with less error-correcting than healthy cells.

Therefore, it’s more sensitive to DNA damage.

Here’s a DNA base, guanine.

Platinum containing agents attach at the number 7 nitrogen atom of two adjacent guanines on the same strand of DNA leading to the formation of cross-bridges, or intra-strand cross-linking of the DNA.

The resultant cross-linking inhibits DNA repair and prevents DNA from being separated for replication, eventually leading to cell death.

Platins are cell cycle-nonspecific agents, meaning they act on tumor cells during all phases of the cell cycle, including the resting G0 phase.

Platins are sometimes described as ‘alkylating-like’ agents as they act like DNA alkylating medications, although they do not have an alkyl group.

Okay, platinum containing agents include cisplatin, carboplatin, and oxaliplatin, which are all administered intravenously and eliminated through the kidneys.

As their names imply, they are coordination complexes of platinum, meaning they consist of a central atom of platinum and a surrounding array of bound molecules, or ions, that are called ligands.

Cisplatin has revolutionized the treatment of solid tumors.

Today, cisplatin and carboplatin are used to treat a variety of solid tumors including testicular, bladder, ovarian, cervical, and lung carcinomas.

They are also used in the treatment of osteosarcoma, which is a common malignant bone tumor in children and teens, which arises from osteoblasts.

Oxaliplatin is used to treat solid tumors including advanced colon cancer, hepatobiliary, pancreatic and ovarian carcinomas.

It is also used in the treatment of lymphomas.

Alright, moving on to the side effects.

Platins can cause gastrointestinal disturbances, including very severe nausea and vomiting, which can be prevented by the use of ondansetron.

It’s also seriously nephrotoxic, which is the main dose-limiting side effect.

We can prevent nephrotoxicity with adequate hydration; diuresis using mannitol, an osmotic diuretic; or saline, to prevent the medications from building up in the kidneys.

Key Takeaways

Platinum-containing medications are a class of drugs that contain platinum and are commonly used to treat. These drugs are cell cycle-nonspecific agents because they target all cell cycle phases. Examples include cisplatin and carboplatin which treat solid malignant tumors like testicular, ovarian, cervical, and lung carcinomas. There is also oxaliplatin, used in advanced colon cancer, hepatobiliary, pancreatic, as well as lymphomas. Side effects of these drugs include nephrotoxicity, neurotoxicity, gastrointestinal disturbances, myelosuppression, and allergic reactions.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Nomograms" D. Nicoll , C. Mark Lu, S.J. McPhee (Eds.), Guide to Diagnostic Tests, 7e. McGraw-Hill (2017)
  5. "Overview of hemostasis" J.C. Aster, H. Bunn (Eds.), Pathophysiology of Blood Disorders, 2e. McGraw-Hill. (2016)
  6. "Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience" Therapeutic Advances in Urology (2019)
  7. "Efficacy and safety of cisplatin for the management of adult patients with oral cancer" Medicine (2019)
  8. "Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors" International Journal of Molecular Sciences (2019)